These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 33117705)

  • 1. Detection of EGFR Mutations in cfDNA and CTCs, and Comparison to Tumor Tissue in Non-Small-Cell-Lung-Cancer (NSCLC) Patients.
    Liu HE; Vuppalapaty M; Wilkerson C; Renier C; Chiu M; Lemaire C; Che J; Matsumoto M; Carroll J; Crouse S; Hanft VR; Jeffrey SS; Di Carlo D; Garon EB; Goldman J; Sollier E
    Front Oncol; 2020; 10():572895. PubMed ID: 33117705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative Mutational Analysis of Circulating Tumor Cells (CTCs) and Plasma-cfDNA Provides Complementary Information for Early Prediction of Relapse: A Pilot Study in Early-Stage Non-Small Cell Lung Cancer.
    Markou AN; Londra D; Stergiopoulou D; Vamvakaris I; Potaris K; Pateras IS; Kotsakis A; Georgoulias V; Lianidou E
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
    Yanagita M; Redig AJ; Paweletz CP; Dahlberg SE; O'Connell A; Feeney N; Taibi M; Boucher D; Oxnard GR; Johnson BE; Costa DB; Jackman DM; Jänne PA
    Clin Cancer Res; 2016 Dec; 22(24):6010-6020. PubMed ID: 27281561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
    Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
    Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development, validation, and comparison of gene analysis methods for detecting
    Hanibuchi M; Kanoh A; Kuramoto T; Saito T; Tobiume M; Saijo A; Kozai H; Kondo M; Morizumi S; Yoneda H; Kagawa K; Ogino H; Sato S; Kawano H; Otsuka K; Toyoda Y; Nokihara H; Goto H; Nishioka Y
    Oncotarget; 2019 Jun; 10(38):3654-3666. PubMed ID: 31217900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A nanowire-based liquid biopsy method using cerebrospinal fluid cell-free DNA for targeted management of leptomeningeal carcinomatosis.
    Choi W; Cho Y; Park SY; Hwang KH; Han JY; Lee Y
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):213-222. PubMed ID: 32705364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of circulating tumor cells and free DNA in non-small cell lung cancer.
    Isobe K; Hata Y; Kobayashi K; Hirota N; Sato K; Sano G; Sugino K; Sakamoto S; Takai Y; Shibuya K; Takagi K; Homma S
    Anticancer Res; 2012 Aug; 32(8):3339-44. PubMed ID: 22843912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer.
    Keup C; Storbeck M; Hauch S; Hahn P; Sprenger-Haussels M; Tewes M; Mach P; Hoffmann O; Kimmig R; Kasimir-Bauer S
    Cancers (Basel); 2019 Feb; 11(2):. PubMed ID: 30781720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolation of circulating tumor cells and detection of EGFR mutations in patients with non-small-cell lung cancer.
    Zhang Q; Nong J; Wang J; Yan Z; Yi L; Gao X; Liu Z; Zhang H; Zhang S
    Oncol Lett; 2019 Apr; 17(4):3799-3807. PubMed ID: 30881500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection.
    Markou Α; Londra D; Tserpeli V; Kollias Ι; Tsaroucha E; Vamvakaris I; Potaris K; Pateras I; Kotsakis Α; Georgoulias V; Lianidou Ε
    Clin Epigenetics; 2022 May; 14(1):61. PubMed ID: 35538556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR.
    Ntzifa A; Kotsakis A; Georgoulias V; Lianidou E
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34073111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02).
    Lee JY; Qing X; Xiumin W; Yali B; Chi S; Bak SH; Lee HY; Sun JM; Lee SH; Ahn JS; Cho EK; Kim DW; Kim HR; Min YJ; Jung SH; Park K; Mao M; Ahn MJ
    Oncotarget; 2016 Feb; 7(6):6984-93. PubMed ID: 26755650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Influence of Different Therapies on EGFR Mutants by Circulating Cell-free DNA of Lung Adenocarcinoma and Prognosis].
    Su F; Zheng K; Fu Y; Wu Q; Tang Y; Wang W; Jiang L
    Zhongguo Fei Ai Za Zhi; 2018 May; 21(5):389-396. PubMed ID: 29764589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Total DNA input is a crucial determinant of the sensitivity of plasma cell-free DNA EGFR mutation detection using droplet digital PCR.
    Zhang Y; Xu Y; Zhong W; Zhao J; Chen M; Zhang L; Li L; Wang M
    Oncotarget; 2017 Jan; 8(4):5861-5873. PubMed ID: 28052016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer.
    Sun W; Yuan X; Tian Y; Wu H; Xu H; Hu G; Wu K
    J Hematol Oncol; 2015 Jul; 8():95. PubMed ID: 26227959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of Cell-Free DNA Collection Tubes for Determination of EGFR Mutation Status in Liquid Biopsy from NSCLC Patients.
    Sesé M; Somoza R; Maestu I; Ureste MM; Sanchez A; Cordoba JF; Sansano I; Venturas G; Ramón Y Cajal S; Hernández-Losa J
    Oncol Ther; 2019 Dec; 7(2):131-139. PubMed ID: 32699985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Analysis of Circulating Cell-Free DNA from Lung Cancer Patients in Routine Laboratory Practice: A Cross-Platform Comparison of Three Different Molecular Methods for Mutation Detection.
    Bartels S; Persing S; Hasemeier B; Schipper E; Kreipe H; Lehmann U
    J Mol Diagn; 2017 Sep; 19(5):722-732. PubMed ID: 28723342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.
    Karachaliou N; Mayo-de las Casas C; Queralt C; de Aguirre I; Melloni B; Cardenal F; Garcia-Gomez R; Massuti B; Sánchez JM; Porta R; Ponce-Aix S; Moran T; Carcereny E; Felip E; Bover I; Insa A; Reguart N; Isla D; Vergnenegre A; de Marinis F; Gervais R; Corre R; Paz-Ares L; Morales-Espinosa D; Viteri S; Drozdowskyj A; Jordana-Ariza N; Ramirez-Serrano JL; Molina-Vila MA; Rosell R;
    JAMA Oncol; 2015 May; 1(2):149-57. PubMed ID: 26181014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance characteristics of a polymerase chain reaction-based assay for the detection of EGFR mutations in plasma cell-free DNA from patients with non-small cell lung cancer using cell-free DNA collection tubes.
    May T; Clement MS; Halait H; Kohlmann A; Kohlmann M; Lai J; Lee N; Li-Sucholeiki X; Meldgaard P; Joshi S; Scudder S; Shrestha N; Sorensen B; Kiral M; O'Donnell P
    PLoS One; 2024; 19(4):e0295987. PubMed ID: 38593164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A lab-on-a-disc platform enables serial monitoring of individual CTCs associated with tumor progression during EGFR-targeted therapy for patients with NSCLC.
    Lim M; Park J; Lowe AC; Jeong HO; Lee S; Park HC; Lee K; Kim GH; Kim MH; Cho YK
    Theranostics; 2020; 10(12):5181-5194. PubMed ID: 32373206
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.